Document Detail


In vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against the cyst form of Toxoplasma gondii.
MedLine Citation:
PMID:  1605598     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The in vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against the cyst form of Toxoplasma gondii were evaluated. In vitro treatment (100 micrograms of 566C80 per ml for 3 days) of cysts isolated from brains of mice infected for 1, 2, 3, 4, or 9 months resulted in loss of viability of the cysts and did not reveal any influence of the duration of in vivo infection on sensitivity to the drug. In vivo experiments to determine the effect of prolonged treatment with 200 mg of 566C80 per kg of body weight per day on cysts in brains of CBA/Ca mice infected with strain ME49 revealed a steady and significant decline in the numbers of cysts compared with the numbers in untreated controls. Histopathology of brains from control mice revealed inflammatory infiltrates around capillaries and in the parenchymas and meninges which were consistently less evident in the brains of treated mice. In addition, cysts were rarely observed in treated mice, whereas extensive inflammation and large numbers of cysts were found throughout the entire brain in control mice infected for the same period. The reduction in the numbers of cysts was evident as early as day 5 of treatment but was more marked at 8 weeks of treatment. The numbers of cysts in the brains of Swiss Webster mice infected for 3 or 6 months also significantly decreased following treatment for 15 or 30 days with the same dose of 566C80. Our results indicate that 566C80 has excellent activity against cysts of T. gondii both in vivo and in vitro and that sensitivity of the cysts to 566C80 is not affected by the duration of the infection in vivo.
Authors:
F G Araujo; J Huskinson-Mark; W E Gutteridge; J S Remington
Related Documents :
803918 - Delayed hypersensitivity and acquired cellular resistance in guinea pigs infected with ...
17371458 - Ccl2-independent role of ccr2 in immune responses against leishmania major.
18321748 - Role of interleukin-12 in determining differential kinetics of invariant natural killer...
18306038 - Effect of lactobacillus casei as a probiotic on modulation of giardiasis.
24082448 - Pyelo-hepatic abscess caused by renal calculi: a rare complication.
7005878 - Prevention of infection on the oncology unit.
Publication Detail:
Type:  Journal Article; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Antimicrobial agents and chemotherapy     Volume:  36     ISSN:  0066-4804     ISO Abbreviation:  Antimicrob. Agents Chemother.     Publication Date:  1992 Feb 
Date Detail:
Created Date:  1992-07-14     Completed Date:  1992-07-14     Revised Date:  2010-09-09    
Medline Journal Info:
Nlm Unique ID:  0315061     Medline TA:  Antimicrob Agents Chemother     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  326-30     Citation Subset:  IM    
Affiliation:
Department of Immunology and Infectious Diseases, Palo Alto Medical Foundation, California 94301, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Antiprotozoal Agents / therapeutic use*
Atovaquone
Brain / parasitology,  pathology
Female
Mice
Mice, Inbred CBA
Naphthoquinones / therapeutic use*
Toxoplasmosis, Animal / drug therapy*,  pathology
Grant Support
ID/Acronym/Agency:
AI04717/AI/NIAID NIH HHS; AI30230/AI/NIAID NIH HHS
Chemical
Reg. No./Substance:
0/Antiprotozoal Agents; 0/Naphthoquinones; 94015-53-9/Atovaquone
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Augmentation of the antibacterial activity of magainin by positive-charge chain extension.
Next Document:  Pharmacokinetics and distribution over the blood brain barrier of two acyclic guanosine analogs in r...